Regeneron Pharmaceuticals | REGN - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
AbbVie USD 3.63B 54M 2026-06
Agenus USD 6.21M 4.34M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amgen USD 1.72B 134M 2026-06
Astellas Pharma JPY 215.07B 19.63B 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
Incyte USD 364.27M 12.54M 2026-09
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
J&J USD 6.25B 168M 2026-09
Kyowa Hakko Kirin JPY 43.74B 2.66B 2026-06
Merck USD 2.86B 25M 2026-09
Moderna USD 216M 43M 2026-06
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Novartis USD 3.14B 296M 2026-03
Pfizer USD 3.41B 496M 2026-06
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.49B 252M 2026-03
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Teva Pharmaceutical Industries USD 1.03B 34M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
United Therapeutics USD 206.7M 50.1M 2026-06
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06